News
DGAP-News: CytoTools AG: HEUTE um 16:00 - Der Vorstand der CytoTools AG im Gespräch mit Aktionären/-innen
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 5. Mai 2022 zu den Ergebnissen für das erste Quartal 2022
DGAP-News: Burcon informiert über aktuelle Entwicklungen
Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity
Quantum Genomics publishes its results for fiscal 2021 and gives an update on its activity
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the
DGAP-News: Abivax veröffentlicht Referenzdokument 2022 'Document d'Enregistrement Universel'
DGAP-News: Heidelberg Pharma AG: Zwischenmitteilung für die ersten drei Monate 2022
QUANTUM GENOMICS : Update of Shareholding Situation Following April 27, 2022 Capital Raise
Update of Shareholding Situation Following April 27, 2022 Capital Raise
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a
DGAP-Adhoc: PAION VERGIBT EXKLUSIVLIZENZ AN CRISTÁLIA FÜR DIE ENTWICKLUNG UND VERMARKTUNG VON REMIMAZOLAM IN LATEINAMERIKA
Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR
Quantum Genomics announces successful capital raising with a gross sum of approximately €15.6 M€
- Quantum Genomics has equipped itself with new financial means to pursue the development of
DGAP-Adhoc: QIAGEN N.V.: QIAGEN erhöht Ausblick für das Gesamtjahr 2022
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M
Quantum Genomics Raises a Gross Amount of Approximately € 15 M
- Launch of capital increase of approximately €15 million for institutional investors with cancellation of the pre-emptive subscription
DGAP-News: CytoTools AG: CytoTools AG startet Kapitalmaßnahme und plant die Ausweitung seines Engagements mit innovativen biomedizinischen Projekten
DGAP-News: Biotest AG: Grifols übernimmt Stimmrechtsmehrheit bei Biotest
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Lyon, France – 25 April 2022 – 7:00 am CEST –Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating
BOIRON : 2022 first quarter sales
(Unaudited data)
In thousands of euros 2022 2021 Variation at current exchange rates Variation at constant exchange rates France 77,055 51,518 +49.6% +49.6% Europe
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-News: BB BIOTECH AG: Etablierte Kernbeteiligungen ermöglichen einen erhöhten Investitionsgrad
DGAP-News: MPH Health Care AG: Vorläufiges IFRS-Ergebnis 2021
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the
Quantum Genomics Announces Granting of New Patents Protecting QGC606
Quantum Genomics Announces Granting of New Patents Protecting QGC606
Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new
QUANTUM GENOMICS : Stéphane Cohen joins Quantum Genomics as Director of Global Operations
Stéphane Cohen joins Quantum Genomics as Director of Global Operations
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new
BOIRON : 2021 results
The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31
Johnson & Johnson Update: ist die Abspaltung gesund oder drohen Probleme?
THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
- · New milestone for NeuroLead, the active agent screening platform
- · New publications in scientific journals
- · Start of Phase I/II clinical trial for Batten disease
Lyon, 28 February 2022
THERANEXUS AND BBDF START RECRUITMENT FOR PHASE I/II TRIAL IN BATTEN DISEASE PATIENTS
Lyon, France – Austin, TX, USA - 3 February 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates